Core Viewpoint - Tianzhihang (688277) has shown a significant increase in stock price and market performance, indicating strong growth potential in the orthopedic surgical robot market, where it holds a leading position [1]. Group 1: Company Performance - As of January 23, 2026, Tianzhihang's stock closed at 23.99 yuan, up 4.62% from the previous week [1]. - The company reached a market capitalization of 10.939 billion yuan, ranking 36th out of 127 in the medical device sector and 1939th out of 5182 in the A-share market [1]. - On January 21, 2026, Tianzhihang recorded two block trades with a total transaction value of 4.0034 million yuan [3]. Group 2: Market Position and Growth - In 2025, the domestic market for orthopedic surgical robots is expected to see over 100 units awarded in procurement, with a year-on-year growth rate of approximately 35% [1]. - Tianzhihang maintains the largest market share in the domestic orthopedic surgical robot sector, with over 70% of the total surgical volume, translating to more than 35,000 surgeries out of 48,500 performed in the first three quarters of 2025 [1][3]. Group 3: Strategic Initiatives - The company is exploring new models such as "purchasing technology services" to reduce upfront costs for medical institutions and enhance the accessibility of surgical robots [1]. - Tianzhihang is actively pursuing international expansion by participating in overseas exhibitions and developing differentiated market strategies to enhance its global competitiveness [1]. - The company's products have received CE certification from the EU, allowing them to meet the demands of high-end markets in developed countries while also being cost-effective for developing nations [1]. Group 4: Industry Developments - The National Healthcare Security Administration has released a guideline to establish a unified pricing project for surgical and treatment auxiliary services, promoting the adoption of robotic surgical technology [2]. - The guideline aims to incentivize companies to develop high-value technologies and guide the industry towards high-quality, standardized development [2].

"此次来到广州观摩学习收获满满。"法国里昂让·默莫兹私立医院外科中心普通外科及消化外科主任拉 斐尔·布尔达里亚(Raphaël Bourdariat)14日在广州表示。他带领3位同院肝胆胰外科专家在中山大学附属 第一医院进行5天的观摩学习，重点聚焦机器人胰腺手术及远程机器人手术技术。 1月13日，在广州市，法国专家在中山大学附属第一医院观摩机器人胰十二指肠切除术。(中山大学 附属第一医院 供图) 中新社广州1月15日电 题：法国医生广州取经：中国机器人手术技术超预期 中新社记者 蔡敏婕 这4位法国医生参与了查房、观摩数台高难度的机器人胰十二指肠切除术及远程机器人手术演示，并与 中山大学附属第一医院团队就机器人胰腺手术的相关问题进行交流。 法国里昂让·默莫兹私立医院外科医生阿扎德·布尔达里亚(Azadeh Bourdariat)坦言："在法国，多数医院 仍以开腹方式开展胰十二指肠切除术，而中国在该手术微创领域积累了大量学术成果。此次观摩了多台 高难度机器人胰十二指肠切除术后，觉得这里的技术水平和学术氛围超出预期。" 负责团队机器人手术推进工作的资深护士威尔弗里德·博洛皮翁(Wilfrid Bolopion)，此 ...